Join the Migraine Prevention group to help and get support from people like you.
Migraine Prevention News (Page 3)
No Link Found Between Migraines, Parkinson's Disease
FRIDAY, Aug. 23, 2024 – Women who suffer frequent migraines don’t have any increased risk of developing Parkinson’s disease, finds a new study that refutes earlier research. “These results are reass...
Migraine in Women Not Linked to Risk for Parkinson Disease
THURSDAY, Aug. 22, 2024 – Migraine is not associated with an increased risk for developing Parkinson disease (PD) among women, according to a study published online Aug. 21 in Neurology. Ricarda S....
Most Traditional Cardiovascular Risk Factors Not Linked to Migraine
WEDNESDAY, July 31, 2024 – For women, many traditional cardiovascular risk factors (CVRFs) are inversely associated with migraine risk, according to a study published online July 31 in Neurology....
High Blood Pressure Might Help Spur Migraines
THURSDAY, Aug. 1, 2024 – High blood pressure might increase a woman’s odds of suffering migraines, a new study finds. Specifically, high diastolic blood pressure is linked to a slightly higher risk o...
Direct CGRP Inhibition Cuts Acne, Rosacea in Patients With Migraine
TUESDAY, July 16, 2024 – For patients experiencing migraine, direct calcitonin gene-related peptide (CGRP) inhibition with monoclonal antibodies (mAbs) is associated with reduced rates of acne and...
FDA Approves Eprontia (topiramate) Oral Solution for Epilepsy and Preventive Treatment of Migraine
WOBURN, MA, November 8, 2021 – Azurity Pharmaceuticals, Inc. a private specialty pharmaceutical company focused on developing innovative products to meet the unique needs of patients with underserved ...
FDA Approves Biohaven's Nurtec ODT (rimegepant) for Preventative Treatment of Migraine
Nurtec ODT 75 mg is the first oral CGRP antagonist approved to prevent migraine Nurtec ODT 75 mg is now the only migraine medication approved to both treat acute migraine attacks and help prevent...
Teva Announces FDA Approval of Ajovy (fremanezumab-vfrm) Injection Autoinjector
PARSIPPANY, N.J.--(BUSINESS WIRE) January 28, 2020 – Teva Pharmaceuticals USA, Inc. an affiliate ofTeva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the Food and Drug...
FDA Approves Aimovig (erenumab-aooe) as a Preventive Treatment for Migraine
May 17, 2018 – The U.S. Food and Drug Administration today approved Aimovig (erenumab-aooe) for the preventive treatment of migraine in adults. The treatment is given by once-monthly...
FDA Approves Topamax for Migraine Prevention in Adolescents
March 28, 2014 – Today, the U.S. Food and Drug Administration approved Topamax (topiramate) for prevention (prophylaxis) of migraine headaches in adolescents ages 12 to 17. This is the first FDA...
FDA Medwatch Alert: Valproate Anti-Seizure Products: Drug Safety Communication - Contraindicated for Pregnant Women for Prevention of Migraine Headaches
Including valproate sodium (Depacon), divalproex sodium (Depakote, Depakote CP, and Depakote ER), valproic acid (Depakene and Stavzor), and their generics ISSUE: FDA is advising health care...
Further information
Related condition support groups
Related drug support groups
clonazepam, lisinopril, metoprolol, bupropion, amitriptyline, amlodipine, propranolol, Topamax, pregabalin, view more... lamotrigine, Depakote, atenolol, topiramate, baclofen, clonidine, nortriptyline, Botox, Emgality, Aimovig, erenumab, Ajovy, verapamil, Qulipta, nifedipine, Nurtec ODT